Scientists test live oral vaccine to block two major causes of Traveler's diarrhea
NCT ID NCT04634513
Summary
This early-stage study tested the safety and immune response of a new oral vaccine designed to prevent two common bacterial causes of severe diarrhea: Shigella and a type of E. coli (ETEC). Healthy adult volunteers received either the vaccine or a placebo in a single dose, and researchers closely monitored them for side effects and signs of an immune response. The main goal was to see if the vaccine was safe and if it triggered the body's defenses against these infections.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHIGELLA INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.